Cohort Study | Female hormone therapy and risk of intracranial hemorrhage from cerebral cavernous malformations

Summary: The study aimed to investigate the association between female hormone therapy (oral contraception or menopausal hormone therapy) and intracranial hemorrhage in female patients with cerebral cavernous malformations (CCM) using data from 2 large prospective cohort studies. The researchers analyzed data from 722 female patients with CCM and found that female hormone therapy use was associated with an increased risk of subsequent intracranial hemorrhage. The risk was more significant among female patients aged 10-44 years using oral contraceptives (adjusted hazard ratio 2·00, 95% CI 1·26-3·17; p=0·003). These findings raise questions about the safety of female hormone therapy in patients with cerebral cavernous malformation.

Article: Female Hormone Therapy and Risk of Intracranial Hemorrhage From Cerebral Cavernous Malformations: A Multicenter Observational Cohort Study – Neurology (link to abstract – $ for full-text – you can try this link for full-text)

Commentary: Oral Contraceptive Use Raises Risk of Intracranial Hemorrhage in Young Females with Cerebral Cavernous Malformations – NeurologyToday